Literature DB >> 26627105

Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.

Rabi Yacoub1, Girish N Nadkarni, Damian Weikum, Ioannis Konstantinidis, Anna Boueilh, Robert M Grant, Kenneth K Mugwanya, Jared M Baeten, Christina M Wyatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26627105      PMCID： PMC4767606          DOI： 10.1097/QAI.0000000000000906

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  24 in total

1.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

2.  HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.

Authors:  Susan P Buchbinder; David V Glidden; Albert Y Liu; Vanessa McMahan; Juan V Guanira; Kenneth H Mayer; Pedro Goicochea; Robert M Grant
Journal:  Lancet Infect Dis       Date:  2014-03-07       Impact factor: 25.071

3.  Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Authors:  Pamela M Murnane; Connie Celum; Nelly Mugo; James D Campbell; Deborah Donnell; Elizabeth Bukusi; Andrew Mujugira; Jordan Tappero; Erin M Kahle; Katherine K Thomas; Jared M Baeten
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

4.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

7.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

8.  Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.

Authors:  Michael Martin; Suphak Vanichseni; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Roman J Gvetadze; Marcel E Curlin; Manoj Leethochawalit; Sithisat Chiamwongpaet; Thitima Cherdtrakulkiat; Rapeepan Anekvorapong; Wanna Leelawiwat; Nartlada Chantharojwong; Janet M McNicholl; Lynn A Paxton; Somyot Kittimunkong; Kachit Choopanya
Journal:  Clin Infect Dis       Date:  2014-05-14       Impact factor: 9.079

9.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

10.  Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Authors:  Samir K Gupta; Albert M Anderson; Ramin Ebrahimi; Todd Fralich; Hiba Graham; Valeska Scharen-Guivel; John F Flaherty; Claude Fortin; Robert C Kalayjian; Anita Rachlis; Christina M Wyatt
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240
View more
  14 in total

Review 1.  Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.

Authors:  Lili Chan; Benjamin Asriel; Ellen F Eaton; Christina M Wyatt
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-03       Impact factor: 2.894

2.  Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?

Authors:  Douglas S Krakower; Kenneth H Mayer
Journal:  J Infect Dis       Date:  2016-04-27       Impact factor: 5.226

3.  Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Authors:  Darrell H S Tan; Mark W Hull; Deborah Yoong; Cécile Tremblay; Patrick O'Byrne; Réjean Thomas; Julie Kille; Jean-Guy Baril; Joseph Cox; Pierre Giguere; Marianne Harris; Christine Hughes; Paul MacPherson; Shannon O'Donnell; Joss Reimer; Ameeta Singh; Lisa Barrett; Isaac Bogoch; Jody Jollimore; Gilles Lambert; Bertrand Lebouche; Gila Metz; Tim Rogers; Stephen Shafran
Journal:  CMAJ       Date:  2017-11-27       Impact factor: 8.262

4.  Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.

Authors:  Vasantha Jotwani; Rebecca Scherzer; David V Glidden; Megha Mehrotra; Patricia Defechereux; Albert Liu; Monica Gandhi; Michael Bennett; Steven G Coca; Chirag R Parikh; Robert M Grant; Michael G Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

Review 5.  Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.

Authors:  Vasantha Jotwani; Mohamed G Atta; Michelle M Estrella
Journal:  J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 10.121

6.  New onset kidney impairment in a large pre-exposure prophylaxis demonstration project in New South Wales, Australia.

Authors:  Gregory M Lucas; Dean L Winslow
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

Review 7.  Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

Authors:  Amit C Achhra; Melinda Nugent; Amanda Mocroft; Lene Ryom; Christina M Wyatt
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

8.  Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Authors:  Rochelle P Walensky; Tim Horn; Nicole C McCann; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2020-03-10       Impact factor: 25.391

9.  Setting the stage for expanding HIV pre-exposure prophylaxis use in Canada.

Authors:  M Hull; Dhs Tan
Journal:  Can Commun Dis Rep       Date:  2017-12-07

10.  HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.

Authors:  Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Judy Shigenaga; Kimberly A Spaulding; David V Glidden; Megha L Mehrotra; Patricia Defechereux; Monica Gandhi; Robert M Grant; Michael G Shlipak; Vasantha Jotwani
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.